The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company aptaTargets and are also participating Aptus Biotech, the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.
aptaTargets participated in the round table about therapeutic aptamers, presenting the nonclinical program.
aptaTargets participated in the round table about therapeutic aptamers, presenting the nonclinical program, regulatory management and preliminary results in First-in-Human trial.
aptaTargets presented the ApTOLL clinical program and nonclinical studies in experimental stroke models.
(European Stroke Organization Conference)
aptaTargets presented the First-in-Human clinical study design.